Protagen, Scienion Ink Partnership | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protagen today announced that Scienion will produce protein microarray batches of more than 1,000 arrays for Protagen for the clinical validation of biomarker panels.

In addition, under a strategic partnership, the two Dortmund, Germany-based firms will jointly evaluate new platforms for multiplexed analytics and co-develop new approaches up to proof-of-concept levels.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.